{"filings":[{"id":2226236,"accession_number":"0001628280-26-056470","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-08-13T11:27:19+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Rockwell Medical made available an updated corporate presentation dated August 13, 2026.","No financial results, guidance, or material events disclosed in the filing body text.","Presentation content not provided in this excerpt; specific figures cannot be summarized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2225636,"accession_number":"0001628280-26-056454","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-08-13T10:14:04+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q2 net sales up 11% to $17.8M; net loss narrows to $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $17.8M, +11% YoY; gross profit $3.2M, +30%; gross margin 18% vs 16%.","Net loss $1.2M vs $1.5M loss; adjusted EBITDA -$0.2M; cash $24.8M at June 30.","Reiterates 2026 guidance: net sales $70-75M, gross margin 18-22%, adj EBITDA $1-2M.","1-for-10 reverse stock split effective July 1, 2026; regained Nasdaq compliance.","New/expanded agreements with Heritage Dialysis and aQua Dialysis during Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1729756,"accession_number":"0001628280-26-048752","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-07-20T10:22:23+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rockwell Medical regains Nasdaq minimum bid price compliance; listing matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 16, 2026 that bid price compliance is regained under Rule 5550(a)(2).","Stock maintained closing bid price of $1.00 or greater from July 1 to July 15, 2026.","Nasdaq has closed the compliance matter; company now in full compliance with all continued listing requirements.","Stock remains listed on Nasdaq Capital Market under ticker RMTI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1314756,"accession_number":"0001628280-26-045866","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-06-29T10:17:03+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Rockwell Medical implements 1-for-10 reverse stock split effective July 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio 1-for-10; effective 12:01 a.m. ET on July 1, 2026.","Stockholder approval obtained at annual meeting on June 12, 2026.","No fractional shares; cash paid in lieu based on June 30 closing price.","Adjustments to equity awards, convertible preferred, and warrants proportional to split.","Trading symbol RMTI unchanged; new CUSIP 774374409."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057356,"accession_number":"0001628280-26-043210","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-06-15T20:27:59+00:00","items":["5.07"],"status":"ready","headline":"Rockwell Medical stockholders approve reverse stock split, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved: 16,993,038 for, 6,597,036 against, 223,632 abstain.","Class II directors Joseph Dawson and Joan Lau reelected with 9.8M and 9.9M votes for, respectively.","Advisory vote on executive compensation passed: 8,232,918 for, 2,682,354 against, 96,595 abstain.","Ratification of EisnerAmper LLP as auditor for 2026 approved: 22,996,530 for, 698,744 against.","Reverse stock split intended to regain compliance with Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90783,"accession_number":"0001628280-26-032987","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rockwell Medical receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice issued May 8, 2026 for failing to meet $1.00 minimum bid price over 30 consecutive business days.","Company has 180 calendar days (until November 4, 2026) to regain compliance.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days.","Reverse stock split proposal included in 2026 Annual Meeting proxy to address the deficiency.","No immediate impact on listing; shares continue trading on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90782,"accession_number":"0001628280-26-031680","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical makes corporate presentation available; no specifics extractable from filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Rockwell Medical made an updated corporate presentation available on May 7, 2026.","The exhibit text (Exhibit 99.1) was not provided in full for analysis.","No quantitative guidance, earnings, or other material metrics are available from this filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90781,"accession_number":"0001628280-26-031629","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 net sales $17.3M (-8% YoY); guides FY26 gross margin 18-22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $17.3M, down 8% from $18.9M; net loss $1.6M vs $1.5M in prior year.","Gross margin improved to 17% from 16%; gross profit $2.9M flat YoY.","FY26 guidance: net sales $70-75M, gross margin 18-22%, Adj. EBITDA $1-2M, positive op. cash flow.","Operational changes expected to generate >$3M annualized additional gross profit.","Cash $23.9M at March 31; final $0.5M Evoqua earnout payment made in April."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":17336000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100574,"accession_number":"0001628280-26-021195","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical files updated corporate presentation; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated March 26, 2026 made available under Item 7.01.","No financial guidance, M&A, leadership changes, or other material events disclosed.","Presentation content is consistent with prior public disclosures; no new metrics or targets provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100573,"accession_number":"0001628280-26-021176","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q4 2025 net sales $18.3M, gross margin 21% (up from 15%), full-year Adj. EBITDA $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net sales $18.3M (vs $24.7M Q4 2024); full-year net sales $69.3M (vs $101.5M) driven by reduced customer purchase volumes.","Q4 2025 gross margin 21% (up from 15% Q4 2024), a company record; full-year gross margin 17% in line with guidance.","Full-year 2025 net loss $5.3M (vs $0.5M loss in 2024) including $4.0M non-cash charges and $1.2M severance/facility costs.","Adjusted EBITDA Q4 2025 $1.0M; full-year $0.3M, second consecutive profitable year on that basis; cash grew to $25.0M.","2026 guidance: Adjusted EBITDA $1M–$2M, positive operating cash flow; pricing increase under extended purchase agreement through Dec 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100572,"accession_number":"0001628280-26-002478","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical prelim Q4 sales ~$18.6M; cash flow positive $2.3M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q4 2025 net sales ~$18.6M; full-year 2025 ~$69.5M (audit pending).","Gross margin improved to ~22% in Q4, up from 14% in Q3 2025.","Q4 cash flow from operations ~$2.3M, second cash-positive quarter; cash & equivalents ~$25M at year-end.","CEO highlighted revenue growth, increased profitability, and portfolio diversification as 2026 focus."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":69258000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100571,"accession_number":"0001628280-26-000221","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rockwell Medical extends DaVita supply agreement to Dec 2026 with price hike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment extends Products Purchase Agreement through Dec 31, 2026.","Amendment provides for a price increase on products sold during the extension term.","Amendment effective December 23, 2025; extension adds one year to original term.","Original agreement with DaVita dated September 18, 2023, previously amended March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116898,"accession_number":"0001104659-25-113452","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rockwell Medical director resigns; Joseph H. Dawson appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Andrea Heslin Smiley resigned Nov 17, 2025; resignation not due to disagreement.","Joseph H. Dawson appointed as Class II director effective Nov 17, 2025, to serve until 2026 annual meeting.","Dawson, 60, former President North America of Nipro Medical (2013-2025), also joined Nominating Committee.","Director compensation: $45k cash retainer + $5k committee fee (pro-rated), plus option for 25k shares and 25k RSUs vesting Nov 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116897,"accession_number":"0001628280-25-051311","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company made available an updated corporate presentation on November 12, 2025.","Presentation covers corporate strategy, business overview, and market positioning.","No earnings, financial guidance, or material operational metrics were included.","Investors are directed to the company's website for the full presentation.","Filing does not contain any new contracts, partnerships, or financial results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116896,"accession_number":"0001628280-25-051267","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q3 net sales fall 44% to $15.9M; net loss of $1.8M vs profit year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $15.9M, down 44% YoY due to largest customer transitioning to another supplier.","Net loss of $1.8M compared to net income of $1.7M in Q3 2024; Adjusted EBITDA virtually breakeven at $50k.","Gross margin contracted to 14% (18% excluding restructuring) from 22% a year ago.","Cash increased to $23.7M from $18.4M at June 30, driven by ATM stock issuance.","Reaffirms 2025 guidance: net sales $65-70M, gross margin 16-18%, Adjusted EBITDA ($0.5M)-$0.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":50912000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133333,"accession_number":"0001104659-25-094524","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rockwell Medical appoints Heather Hunter as SVP & COO effective Sept 23, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Hunter appointed SVP & COO effective Sept 23, 2025; previously SVP & Chief Corporate Affairs Officer since Aug 2022.","Annual base salary $323,574; target bonus 45% of base salary; eligible for long-term incentive grants.","Initial time-based option grant of 60,000 shares, vesting over 4 years from Aug 29, 2022.","Severance upon termination without cause/good reason: 12 months base salary plus COBRA reimbursement.","Change of control severance: lump sum 1x base salary plus prorated target bonus; full acceleration of time-based awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133332,"accession_number":"0001041024-25-000009","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.","Net loss $1.5M vs net income $0.3M in Q2 2024; Adjusted EBITDA -$0.2M vs $1.4M year ago.","Cash & investments increased to $18.4M, supported by $1.8M operating cash flow.","Reaffirmed 2025 guidance: net sales $65-70M, gross margin 16-18%, Adj EBITDA -$0.5M to $0.5M.","Secured multi-year supply agreements with Innovative Renal Care (3-yr) and other providers; >80% customers under long-term contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":34985000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149998,"accession_number":"0001104659-25-050997","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rockwell Medical shareholders elect directors, approve advisory say-on-pay and 5M share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors John G. Cooper and Allen Nissenson, MD re-elected with 14.3M and 14.4M votes for, respectively.","Advisory vote on executive compensation passed with 13.3M for, 1.1M against, 0.55M abstain, and 8.4M broker non-votes.","Ratification of EisnerAmper LLP as auditor for 2025 approved: 21.8M for, 0.36M against, 1.2M abstain.","Amendment to 2018 Long Term Incentive Plan increasing shares by 5,000,000 approved: 12.9M for, 2.0M against, 0.05M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149997,"accession_number":"0001628280-25-024444","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation made available on May 12, 2025 under Item 7.01.","Specific content and figures from the presentation are not provided in the filing.","No new financial guidance, material events, or operational changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149996,"accession_number":"0001104659-25-046957","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 net sales $18.9M (-17% YoY); net loss improves to $1.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales fell 17% to $18.9M, driven by largest customer transitioning to another supplier.","Received a one-time non-refundable payment of $0.9M from that customer to ensure supply continuity.","Net loss improved 12% to $1.5M ($0.04 loss per share) vs $1.7M in Q1 2024.","Adjusted EBITDA was -$0.4M; cash and investments $17.3M, down $4.3M from year-end 2024.","Reaffirmed 2025 guidance: net sales $65M-$70M, gross margin 16%-18%, adjusted EBITDA -$0.5M to $0.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":18914000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169008,"accession_number":"0001628280-25-014017","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation; no specific new details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed Item 7.01 Regulation FD disclosure with corporate presentation dated March 20, 2025.","No material financial or operational data from the presentation is included in the 8-K or summary.","Presentation is furnished, not filed, and not incorporated by reference into SEC filings.","Investors should refer to the full presentation for any potential updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169007,"accession_number":"0001104659-25-025782","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Reports Record Net Sales and First Full-Year Adjusted EBITDA Profitability in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales of $101.5M in 2024, a 21% increase over 2023.","Record gross profit of $17.5M in 2024, a 101% increase over 2023.","Full-year adjusted EBITDA reached $5.2M, first time profitable on that basis.","Net loss improved 94% to $0.5M in 2024 from $8.4M in 2023.","Largest customer transitioning away; expects ~$34M revenue loss in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186092,"accession_number":"0001104659-24-128064","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Rockwell Medical appoints Jesse Neri as CFO effective December 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jesse Neri, previously SVP Finance since Oct 2023, becomes CFO and Principal Financial Officer.","Annual base salary of $300,000; target bonus 45% of base salary.","Received initial option grant of 75,000 shares vesting over 4 years.","Neri had served as SVP Finance and principal accounting officer since Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186091,"accession_number":"0001104659-24-117447","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rockwell Medical files prospectus supplement for up to $25M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new S-3 shelf registration on Oct 8, effective Oct 21, replacing expiring prior shelf.","Prospectus supplement filed Nov 13 covers up to $25M of common stock under Cantor Fitzgerald sales agreement.","Sales agreement dated April 8, 2022; this supplement updates the at-the-market offering capacity.","Legal opinion from Gibson Dunn on securities legality attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186090,"accession_number":"0001628280-24-046835","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical provides updated corporate presentation; no specific financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished an updated corporate presentation as Exhibit 99.1 to Form 8-K on November 12, 2024.","Presentation content is not provided in the filing; no new financial or operational figures are available.","Filing is under Regulation FD; presentation is furnished, not filed, and not incorporated by reference.","Investors should refer to the actual presentation for any updates on strategy or performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186089,"accession_number":"0001628280-24-046792","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q3 2024 net income $1.7M, raises guidance; largest customer revenue expected to decline $31-38M in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $28.3M (+31% YoY); gross profit $6.2M (+183%); gross margin 22% vs 9%.","Net income $1.7M vs loss $1.9M in Q3 2023; adjusted EBITDA $2.8M vs negative $1.2M.","Cash from operations $4.3M; cash and equivalents $18.3M, up from $11.9M at June 30.","2024 guidance raised: net sales $98-101M, gross profit $15-17M, adjusted EBITDA $4-5M.","Largest customer extended through Dec 2025 but expects volume decline of $31-38M in 2025; company aims to offset with new contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":76824000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202707,"accession_number":"0001628280-24-036211","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical issues updated corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made available on August 8, 2024 under Item 7.01 Regulation FD.","No financial or operational data from the presentation included in the 8-K filing.","Investors should refer to the presentation itself for any updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202706,"accession_number":"0001628280-24-035830","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q2 net sales $25.8M (+43% YoY), net income $0.3M, raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $25.8M (+43% YoY); gross profit $4.6M (+341%); gross margin expanded to 18% from 6%.","Net income $0.3M vs net loss of $3.3M in Q2 2023; adjusted EBITDA $1.5M vs negative $2.3M.","Generated $1.4M in cash flow from operations; cash and equivalents rose to $11.9M from $8.6M.","FY 2024 net product sales guidance raised to $95M–$98M (from $90M–$94M) and Adjusted EBITDA to $0.75M–$1.5M.","Promoted Tim Chole to Chief Commercial Officer; amended Evoqua asset purchase agreement for extended payment terms."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":48508000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202705,"accession_number":"0001104659-24-079679","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Rockwell Medical amends asset purchase deal with Evoqua; affirms 2024 gross margin guidance of 14-16%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment reduces First Deferred Payment by $322,260 to $2,177,740, payable in four quarterly installments through April 2025.","Second Deferred Payment of $2.5M payable in four quarterly installments from July 2025 to April 2026.","CEO reaffirmed 2024 non-GAAP gross margin guidance of 14-16% at HC Wainwright conference, correcting a prior misstatement of 13-15% that referred to gross profit dollars.","Amendment clarifies undeliverable equipment is excluded from acquired assets and includes a release of claims related to expired inventory disposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218866,"accession_number":"0001628280-24-025011","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rockwell Medical shareholders elect directors, approve compensation, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Robert Radie and Mark Strobeck elected Class III directors with ~11.5M votes each; broker non-votes ~8.1M.","Advisory say-on-pay resolution approved: 11,126,598 for, 522,245 against, 83,718 abstain.","EisnerAmper LLP ratified as independent auditor for 2024 with 19,446,483 for, 210,240 against, 193,112 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218865,"accession_number":"0001628280-24-023287","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation; details not disclosed in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Item 7.01 disclosure: company made available an updated corporate presentation on May 14, 2024.","Presentation furnished as Exhibit 99.1; no specific financial or operational data extracted.","Form 8-K states information is furnished, not filed, and not incorporated by reference.","No new material events or changes are explicitly described beyond the availability of the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218864,"accession_number":"0001628280-24-023035","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 record sales $22.7M (+15% YoY); raises 2024 guidance across all metrics","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net sales $22.7M (record), up 15% YoY; ex-deferred revenue, up 25%. Gross profit $3.1M (+18% YoY).","Net loss improved to $1.7M from $1.8M YoY; adjusted EBITDA ($0.5M) vs ($1.0M).","Raised FY2024 guidance: net sales $90-94M (prev $84-88M); gross profit $13-15M; adjusted EBITDA $0.5-1.0M.","Amended Innovatus loan: rate reduced, maturity extended to Jan 2029; interest-only through Sep 2026.","New distribution deals with BioNuclear and AMI expected ~$1M annual revenue; new supply agreement with large Mountain West health system."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":22676000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238768,"accession_number":"0001628280-24-012367","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation on March 21, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed as Exhibit 99.1; specific content (strategy, financials, pipeline) not reproduced in 8-K text.","Investors should review the presentation directly for any material updates.","No new financial metrics, guidance, or operational changes disclosed in the filing itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238767,"accession_number":"0001104659-24-036897","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical posts record 2023 net sales of $83.6M; achieves first-ever adjusted EBITDA profit in Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net sales $22.1M (+14% YoY); Q4 adjusted EBITDA $0.5M vs ($0.6M) in Q4 2022, first positive quarter in company history.","Full-year 2023 net sales $83.6M (+15% YoY); gross profit $8.7M (+114% YoY); net loss improved 55% to ($8.4M).","2024 guidance: net product sales $84-88M (5-10% growth), gross margin 14-16%, and full-year adjusted EBITDA $0-0.5M.","Amended Innovatus loan: interest rate reduced, maturity extended to Jan 2029; interest-only payments for 30-36 months.","Acquired Evoqua hemodialysis concentrates assets in July 2023; became leading US liquid bicarbonate supplier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238766,"accession_number":"0001628280-24-000874","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical provides updated corporate presentation; no specific financial metrics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation made available on January 8, 2024.","Presentation likely covers business strategy and market opportunity; no earnings or guidance update included.","No new material financial data or forward-looking statements were furnished with this 8-K.","Content of the presentation is not summarized, so materiality cannot be assessed from the filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238765,"accession_number":"0001104659-24-002065","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["1.01","2.02","8.01","2.03","3.02","9.01"],"status":"ready","headline":"Rockwell Medical extends loan maturity to 2029, provides preliminary Q4 net sales $21.3M-$22.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Amended loan with Innovatus: $8.0M principal, interest-only 30-36 months, maturity extended from Mar 2025 to Jan 2029.","Issued warrant to Innovatus for 191,096 shares at $1.83 per share, exercisable through Jan 2029.","Preliminary Q4 2023 net sales $21.3M-$22.3M (10-16% YoY growth); gross profit $1.6M-$2.6M; adj. EBITDA ($0.9M)-$0.1M.","Full-year 2023 net sales projected $82.8M-$83.8M (14-15% growth); gross profit $7.4M-$8.4M; adj. EBITDA ($5.5M)-($4.5M).","Cash and equivalents $11.0M at Dec 31, 2023, down slightly from $11.7M at Sep 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":83612000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256258,"accession_number":"0001628280-23-038786","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; details not available in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made available an updated corporate presentation on November 14, 2023, as Exhibit 99.1.","No specific financial figures, guidance, or operational updates disclosed in the 8-K filing.","Exhibit content is a truncated filename ('rmtiq323investorpresenta'); full presentation not provided.","Disclosure is routine Regulation FD; no material changes evident from available text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256257,"accession_number":"0001104659-23-117573","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q3 revenue $23.8M, gross profit up 183% YoY; expects adjusted EBITDA profitability in Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $23.8M, highest to-date; concentrates sales $21.6M, up 27% YoY.","Operating loss $1.7M, improved 53% YoY; net loss $1.9M vs $4.2M in Q3 2022.","2023 guidance reaffirmed: net sales $82-86M (+17-18% YoY), gross profit $8-10M (+95-144% YoY).","Company now expects adjusted EBITDA profitability in Q4 2023, ahead of prior 2024 target.","Acquired Evoqua hemodialysis concentrates assets; became leading US supplier of liquid bicarbonate."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":61519000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256256,"accession_number":"0001104659-23-109482","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rockwell Medical appoints Joan Lau, PhD to board as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expands from six to seven; Dr. Lau appointed Class II director, term until 2026 annual meeting.","Dr. Lau receives $45k annual cash retainer (pro-rated), option for 25k shares, and 25k RSUs, vesting Oct 16, 2024.","Dr. Lau is CEO of Spirovant Sciences, partner at Militia Hill Ventures, and serves on Brandywine Realty Trust board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273664,"accession_number":"0001628280-23-032719","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Rockwell Medical amends DaVita supply agreement with price increase, one-time payment","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["DaVita agrees to increased product pricing for dialysis concentrates effective Sept 1, 2023, plus a one-time payment to Rockwell after Dec 1, 2023.","Amended agreement runs through Dec 31, 2024; DaVita can extend to Dec 31, 2025 with further price increase.","DaVita must provide 9-month purchase forecasts and commit to buy at least forecasted amounts or pay shortfall.","Upon termination, Rockwell will provide transition services to DaVita if requested."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273663,"accession_number":"0001104659-23-101184","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rockwell Medical CAO Paul McGarry resigns effective Sept 29, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul McGarry resigns as SVP Finance and CAO, effective Sept 29, 2023, to pursue other opportunities.","He will remain in role through effective date and provide consulting until Q3 2023 filing and as needed.","No replacement named; company transition assistance expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273662,"accession_number":"0001628280-23-032023","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; specific content not disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated September 12, 2023, made available via Form 8-K.","No financial or operational updates were included in the filing body.","Presentation content is not summarized; investors should review exhibit directly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273661,"accession_number":"0001628280-23-029166","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical acquires Evoqua concentrates, raises guidance, expects Q4 profitability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 net loss $3.3M ($0.18/sh) vs $5.0M loss ($0.43/sh) in Q2 2022; net sales $18.1M vs $18.7M prior year.","Acquired Evoqua concentrates business for $12.2M; Evoqua generated $18M annual revenue and $3.3M annual EBITDA.","Increased 2023 net sales guidance to $82-86M (from $78-82M) and gross profit guidance to $8-10M (from $7-9M).","Expects to achieve profitability from operations in Q4 2023 and going forward.","Pro forma cash $16.2M after $13.8M warrant exercise and acquisition funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":37748000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273660,"accession_number":"0001104659-23-079774","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["1.01","2.02","8.01","3.02","3.03","7.01","9.01"],"status":"ready","headline":"Rockwell Medical acquires Evoqua hemodialysis concentrates business for $16M total consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition for $11M cash at closing plus two $2.5M installments at 12 and 24 months.","Funded from cash; post-close cash was $15.3M.","Acquired business generated ~$18M trailing revenue and >$3.3M EBITDA.","2023 revenue guidance raised to $82-86M from prior expectation.","Preliminary Q2 2023 revenue $18.0-18.3M, net loss per share pro forma $(1.31) for FY 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290686,"accession_number":"0001628280-23-019450","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rockwell Medical shareholders elect directors, approve 1.6M share equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mark Ravich and Andrea Heslin Smiley elected Class II directors; Ravich received 2,015,069 for, 873,941 against; Smiley 2,639,034 for, 249,295 against.","Advisory vote on executive compensation approved: 2,485,037 for, 337,531 against.","Frequency of say-on-pay set at 1 year (2,704,562 votes for 1 year).","Ratification of EisnerAmper LLP as auditor for 2023: 7,696,517 for, 119,313 against.","Amendment to 2018 Long Term Incentive Plan to increase reserved shares by 1,600,000 approved: 1,994,126 for, 825,079 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290685,"accession_number":"0001628280-23-018230","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical furnishes updated corporate presentation; no material news disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation furnished as Exhibit 99.1 on May 15, 2023.","Filing does not include financial results, guidance changes, or material events.","Presentation likely covers company strategy, product pipeline, and market overview.","No specific numbers, names, or dates beyond the presentation availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290684,"accession_number":"0001628280-23-017984","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rockwell Medical Q1 revenue $19.7M (+22.4% YoY); net loss narrows to $0.10/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $19.7M, up 22.4% YoY; gross profit of $2.6M vs gross loss of $0.8M in Q1 2022.","Net loss of $1.75M ($0.10/share) vs $7.2M ($0.84) a year ago; operating loss improved to $1.4M.","Reiterates 2023 guidance: revenue $78-82M, gross profit $7-9M, targeting profitability in 2024.","Signed long-term supply agreements with largest U.S. non-profit dialysis provider and Concerto Renal Services.","Assumed full commercial responsibility for Baxter customers; cash stood at $16.8M at quarter-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":19668000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290681,"accession_number":"0001104659-23-045153","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K/A","filed_at":"2023-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rockwell Medical dismisses Marcum, appoints Eisner as new auditor effective April 10, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board dismissed Marcum LLP as independent auditor effective April 10, 2023.","Eisner appointed as new independent registered public accounting firm for FY 2023.","No disagreements or reportable events occurred during Marcum's tenure in FY 2021 and 2022.","Auditor change follows a competitive process led by the Board and Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290683,"accession_number":"0001628280-23-011517","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rockwell Medical dismisses Marcum LLP, appoints EisnerAmper as auditor effective April 10, 2023","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Marcum LLP dismissed as independent auditor effective April 7, 2023 after competitive review.","EisnerAmper LLP appointed as new independent auditor for fiscal year ending December 31, 2023.","No disagreements or reportable events with Marcum during fiscal 2021, 2022, or interim period.","Marcum's audit reports for 2021 and 2022 were unqualified with no adverse opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290682,"accession_number":"0001628280-23-011136","cik":1041024,"company_name":"ROCKWELL MEDICAL, INC.","ticker":"RMTI","form_type":"8-K","filed_at":"2023-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Rockwell Medical posts updated corporate presentation; no material new facts disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation dated April 1, 2023 made available on April 10, 2023.","Presentation content not detailed in filing; specific figures or strategic updates unknown.","Filed under Regulation FD; information is furnished, not filed, per 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":30159258.6067505,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-10T23:59:59+00:00|290682"}